24.69

0.60% -0.15

Catalyst Pharmaceuticals Inc (CPRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CPRX? Forum Prognose

Schlusskurs vom Vortag:

$24.84

Offen:

$24.9

24-Stunden-Volumen:

937.55K

Relative Volume:

0.78

Marktkapitalisierung:

$3.02B

Einnahmen:

$460.48M

Nettoeinkommen (Verlust:

$142.80M

KGV:

20.92

EPS:

1.18

Netto-Cashflow:

$221.79M

1W Leistung:

+1.90%

1M Leistung:

+13.99%

6M Leistung:

+26.23%

1J Leistung:

+54.89%

1-Tages-Spanne:

$24.25

$24.98

1-Wochen-Bereich:

$24.25

$26.16

52-Wochen-Spanne:

$14.47

$26.16

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Firmenname

Catalyst Pharmaceuticals Inc

Sektor

Healthcare (1166)

Branche

Biotechnology (671)

Telefon

(305) 529-2522

Adresse

355 ALHAMBRA CIRCLE, CORAL GABLES

Mitarbeiter

Twitter

@CatalystForRare

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

CPRX's Discussions on Twitter

Vergleichen Sie CPRX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CPRX Catalyst Pharmaceuticals Inc	24.69	3.02B	460.48M	142.80M	221.79M	1.18
VRTX Vertex Pharmaceuticals Inc	492.69	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	637.36	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	589.15	35.93B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	268.46	34.75B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	267.39	28.24B	3.81B	-644.79M	-669.77M	-6.24

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-04	Eingeleitet	Robert W. Baird	Outperform
2024-11-18	Eingeleitet	Stephens	Overweight
2024-03-14	Eingeleitet	Citigroup	Buy
2024-03-07	Eingeleitet	BofA Securities	Buy
2023-12-21	Eingeleitet	Oppenheimer	Outperform
2022-08-24	Herabstufung	ROTH Capital	Buy → Neutral
2018-09-21	Eingeleitet	Cantor Fitzgerald	Overweight
2018-09-07	Fortgesetzt	Piper Jaffray	Overweight
2016-10-05	Hochstufung	Piper Jaffray	Neutral → Overweight
2016-04-26	Herabstufung	Piper Jaffray	Overweight → Neutral
2014-09-30	Bestätigt	ROTH Capital	Buy
2014-09-16	Bestätigt	ROTH Capital	Buy
2014-09-15	Bestätigt	H.C. Wainwright	Buy
2013-10-21	Bestätigt	Aegis Capital	Buy
2013-09-24	Eingeleitet	Maxim Group	Buy
2013-09-06	Bestätigt	Aegis Capital	Buy
2013-04-18	Eingeleitet	Aegis Capital	Buy
2012-08-27	Hochstufung	Rodman & Renshaw	Mkt Perform → Mkt Outperform
2009-10-01	Hochstufung	Merriman	Sell → Neutral
2009-05-29	Herabstufung	Hapoalim	Neutral → Underperform
2009-05-29	Herabstufung	Merriman Curhan Ford	Buy → Sell
2008-12-15	Eingeleitet	Merriman Curhan Ford	Buy
2007-11-28	Eingeleitet	Rodman & Renshaw	Mkt Outperform
2007-01-31	Eingeleitet	Stifel Nicolaus	Buy
2007-01-05	Eingeleitet	First Albany	Buy

Alle ansehen

Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten

Mar 28, 2025

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - Insider Monkey

Mar 27, 2025

Mar 25, 2025

With 81% ownership in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX), institutional investors have a lot riding on the business - Yahoo Finance

Mar 25, 2025

Catalyst (CPRX) Surges 6.2%: Is This an Indication of Further Gains? - Yahoo Finance

Mar 25, 2025

Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) large institutional owners must be happy as stock continues to impress, up 18% over the past week - Simply Wall St

Mar 25, 2025

Mar 24, 2025

Santhera to share latest on commercial rollout of AGAMREE® and future strategic priorities at Capital Markets Day - GlobeNewswire Inc.

Mar 24, 2025

Mar 21, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Mar 21, 2025

Mar 17, 2025

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings - Yahoo Finance

Mar 17, 2025

Mar 14, 2025

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Healthcare Stock For Long-Term Investment? - Insider Monkey

Mar 14, 2025

Mar 13, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Mar 13, 2025

Bank of New York Mellon Corp Raises Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

Mar 13, 2025

Mar 12, 2025

Catalyst Pharmaceuticals Inc. stock rises Wednesday, still underperforms market - MarketWatch

Mar 12, 2025

Mar 11, 2025

Proficio Capital Partners LLC Makes New $339,000 Investment in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World

Mar 11, 2025

Catalyst Pharmaceuticals: Undervalued Future With Multiple Upside Catalysts - Seeking Alpha

Mar 11, 2025

Mar 10, 2025